ClinicalTrials.Veeva

Menu

Natural History Study for DNA Repair Disorders

University of Minnesota (UMN) logo

University of Minnesota (UMN)

Status

Enrolling

Conditions

Xeroderma Pigmentosum
Cockayne Syndrome
DNA Repair Disorder
Trichothiodystrophy

Treatments

Other: Gait Assessment
Other: Interval History
Other: Physical Examination
Other: ECAB Assessment
Other: Specimen Sample Collection

Study type

Observational

Funder types

Other

Identifiers

NCT05484570
NEUR-2022-30942

Details and patient eligibility

About

This will be a single-center, single-arm, non-interventional natural history study to evaluate the longitudinal clinical course, functional outcome measures, and candidate biomarkers for individuals with DNA repair disorders, including Cockayne syndrome (CS), xeroderma pigmentosum (XP), and trichothiodystrophy (TTD).

Full description

This will be a single-center, single-arm, non-interventional natural history study to evaluate the longitudinal clinical course, functional outcome measures, and candidate biomarkers for individuals with DNA repair disorders, including Cockayne syndrome (CS), xeroderma pigmentosum (XP), and trichothiodystrophy (TTD). Our hypothesis is that a reliable and reproducible baseline natural history course can be established for DNA repair disorders using the Early Childhood Assessment of Balance (ECAB) as a primary endpoint and other measures as secondary and exploratory endpoints that may be used in future therapeutic clinical trials.

Enrollment

40 estimated patients

Sex

All

Ages

6+ months old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Diagnosis of Cockayne syndrome (CS), xeroderma pigmentosum (XP), or trichothiodystrophy (TTD), based on genetic testing and/or key clinical characteristics l characteristics
  • Has one or more of the following neurodevelopmental or neurological complications
  • Gross motor delay (non-ambulatory or started walking after age 18 months)
  • Language delay (non-verbal or started talking after 18 months)
  • Altered muscle tone (hypertonia, dystonia, hypotonia)
  • Gait difficulties, including stiff gait, short stride, frequent falls, use of orthotics, use of walker
  • Tremors
  • Microcephaly
  • Is a family member of an individual with the above condition
  • No restrictions regarding current ambulatory status
  • Minimum age for enrollment eligibility will be 6 months due to fragility of neonates with severe forms of DNA repair disorders and limitations of motor assessment scales in infants younger than 6 months. There will be no maximum age for enrollment eligibility.
  • No restrictions regarding gender, race, or ethnicity.
  • Voluntary written consent from the participant if adult capable of consenting or parent/guardian if minor or not capable of consenting
  • Written consent of Legally Authorized Representative if enrolling adult lacks capacity to consent

Exclusion criteria

  • Any prior history of systemic gene or cell-based therapy
  • Current participation in an interventional clinical trial

Trial design

40 participants in 2 patient groups

Diagnosed
Description:
Patients who are diagnosed with a DNA Repair Disorder
Treatment:
Other: Specimen Sample Collection
Other: ECAB Assessment
Other: Gait Assessment
Other: Physical Examination
Other: Interval History
Control
Description:
Healthy family members of enrolled diagnosed participants.
Treatment:
Other: Specimen Sample Collection
Other: ECAB Assessment
Other: Gait Assessment

Trial contacts and locations

1

Loading...

Central trial contact

Erin Aguero

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems